|
|
|
| 
|
|
|
My Recent Searches
|
|
|
|
|
|
|
|
|
Cincor Pharma, Inc. (CINC) |
|
|
$0.00 0.00 (0.00%) as of 4:30 Tue 11/30
|
|
Download |
|
|
| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
43,764,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0 - $0 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile CinCor Pharma is a biopharmaceutical company focused on developing its primary clinical candidate, CIN-107, for the treatment of hypertension and other cardio-renal diseases. CIN-107 is an oral small molecule inhibitor of aldosterone synthase, the enzyme responsible for the synthesis of aldosterone in the adrenal gland. CIN-107 inhibits aldosterone synthase activity, providing a differentiated mechanism for lowering aldosterone activity via a reduction of aldosterone synthesis, with the goal of providing an improved treatment for patients suffering from hypertension, or high blood pressure. Co. is developing CIN-107 for the indication of chronic kidney disease and primary aldosteronism.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
1,905,333 |
| Total Buy Value |
$0 |
$0 |
$0 |
$57,159,990 |
| Total People Bought |
0 |
0 |
0 |
6 |
| Total Buy Transactions |
0 |
0 |
0 |
6 |
| Total Shares Sold |
0 |
0 |
0 |
6,006 |
| Total Sell Value |
$0 |
$0 |
$0 |
$86,011 |
| Total People Sold |
0 |
0 |
0 |
2 |
| Total Sell Transactions |
0 |
0 |
0 |
2 |
| End Date |
2024-02-18 |
2023-11-17 |
2023-05-19 |
2022-05-19 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Katabi Maha |
10% Owner |
– – • |
2022-08-11 |
4 |
B |
$30.00 |
$15,000,000 |
I/I |
500,000 |
6,073,949 |
1.5 |
- |
|
| General Atlantic Genpar (lux) Scsp |
10% Owner |
– – • |
2022-08-11 |
4 |
B |
$30.00 |
$2,490,000 |
I/I |
83,000 |
4,209,470 |
1.5 |
- |
|
| Healy James |
Director |
– • • |
2022-08-05 |
4 |
OE |
$13.60 |
$399,990 |
D/D |
29,411 |
29,411 |
|
- |
|
| Freeman Mason |
Chief Medical Officer |
• – – |
2022-06-10 |
4 |
S |
$15.21 |
$91 |
D/D |
(6) |
2,494 |
|
- |
|
| General Atlantic (spv) Gp, Llc |
10% Owner |
– – • |
2022-01-11 |
4 |
B |
$16.00 |
$27,200,000 |
I/I |
1,700,000 |
4,126,470 |
1.5 |
- |
|
| General Atlantic (spv) Gp, Llc |
10% Owner |
– – • |
2022-01-11 |
4 |
A |
$0.00 |
$0 |
I/I |
2,426,470 |
2,426,470 |
|
- |
|
| Freeman Mason |
EVP Clinical Development |
• – – |
2022-01-11 |
4 |
B |
$16.00 |
$1,600 |
I/I |
100 |
100 |
1.91 |
- |
|
| Freeman Mason |
EVP Clinical Development |
• – – |
2022-01-11 |
4 |
B |
$16.00 |
$40,000 |
D/D |
2,500 |
2,500 |
2.74 |
- |
|
| Pearce Catherine |
Chief Operating Officer |
• – – |
2022-01-11 |
4 |
B |
$16.00 |
$24,000 |
I/I |
1,500 |
1,500 |
1.99 |
- |
|
| Pearce Catherine |
Chief Operating Officer |
• – – |
2022-01-11 |
4 |
B |
$16.00 |
$12,000 |
D/D |
750 |
130,911 |
2.74 |
- |
|
| Healy James |
Director |
– • • |
2022-01-11 |
4 |
B |
$16.00 |
$5,200,000 |
I/I |
325,000 |
5,573,949 |
2.25 |
- |
|
| Healy James |
Director |
– • • |
2022-01-11 |
4 |
A |
$0.00 |
$0 |
I/I |
5,248,949 |
5,248,949 |
|
- |
|
| Katabi Maha |
10% Owner |
– – • |
2022-01-11 |
4 |
B |
$16.00 |
$5,200,000 |
I/I |
325,000 |
5,573,949 |
1.5 |
- |
|
| Katabi Maha |
10% Owner |
– – • |
2022-01-11 |
4 |
A |
$0.00 |
$0 |
I/I |
5,248,949 |
5,248,949 |
|
- |
|
| De Garidel Marc |
Chief Executive Officer |
• • – |
2022-01-11 |
4 |
B |
$16.00 |
$200,000 |
D/D |
12,500 |
12,500 |
2.81 |
- |
|
| Cinrx Pharma, Llc |
10% Owner |
– – • |
2022-01-11 |
4 |
A |
$0.00 |
$0 |
D/D |
1,222,530 |
3,630,103 |
|
- |
|
| Sofinnova Capital Ix |
10% Owner |
– – • |
2022-01-11 |
4 |
B |
$16.00 |
$3,520,000 |
I/I |
220,000 |
4,087,646 |
1.5 |
- |
|
| Sofinnova Capital Ix |
10% Owner |
– – • |
2022-01-11 |
4 |
A |
$0.00 |
$0 |
I/I |
3,867,646 |
3,867,646 |
|
- |
|
| General Atlantic Genpar (lux) Scsp |
10% Owner |
– – • |
2022-01-11 |
4 |
B |
$16.00 |
$27,200,000 |
I/I |
1,700,000 |
4,126,470 |
1.5 |
- |
|
| General Atlantic Genpar (lux) Scsp |
10% Owner |
– – • |
2022-01-11 |
4 |
A |
$0.00 |
$0 |
I/I |
2,426,470 |
2,426,470 |
|
- |
|
| Parmar Kush |
10% Owner |
– – • |
2022-01-11 |
4 |
B |
$16.00 |
$7,520,000 |
I/I |
470,000 |
496,323 |
1.5 |
- |
|
| Parmar Kush |
10% Owner |
– – • |
2022-01-11 |
4 |
A |
$0.00 |
$0 |
I/I |
3,867,646 |
183,823 |
|
- |
|
| Coelho Mary Theresa |
EVP CFO & Chief BD Officer |
• – – |
2022-01-11 |
4 |
B |
$16.00 |
$1,600 |
I/I |
100 |
100 |
1.91 |
- |
|
| Cinrx Pharma, Llc |
10% Owner |
– – • |
2022-01-06 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
2,407,573 |
|
- |
|
49 Records found
|
|
Page 2 of 2 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
